Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus

Akito Tsutsumi, Eiji Matsuura, Kenji Ichikawa, Atsushi Fujisaku, Masaya Mukai, Seiichi Kobayashi, Takao Koike

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

Objective. To investigate whether anticardiolipin antibodies (aCL) in patients with systemic lupus erythematosus (SLE) bind to β2-glycoprotein I (β2GPI), and to search for a relationship between the presence of IgG and/or IgM anti-β2GPI antibody and clinical manifestations in SLE patients. Methods. IgG and IgM anti-β2GPI in 308 Japanese SLE patients were measured using phospholipid-independent enzyme immunoassays. Relationships to clinical histories and to various laboratory data were examined. Results. The values of anti-β2GPI and aCL, as measured by conventional enzyme immunoassay, showed a strong correlation, but the anti-β2GPI assay was more useful in distinguishing β2GPI-dependent aCL from β2GPI-independent aCL. The presence of IgG anti-β2GPI was associated with an increased frequency of a history of thrombosis. Comparisons of various laboratory data suggested that the titer of anti-β2GPI may fluctuate with disease activity. Conclusion. The results suggest that pathogenic aCL is directed against structurally altered β2GPI and that enzyme immunoassay for anti-β2GPI may prove useful in evaluating the risk of thrombosis and monitoring the clinical course in patients with SLE.

Original languageEnglish
Pages (from-to)1466-1474
Number of pages9
JournalArthritis and Rheumatism
Volume39
Issue number9
Publication statusPublished - Sep 1996
Externally publishedYes

Fingerprint

Systemic Lupus Erythematosus
Glycoproteins
Antibodies
Anticardiolipin Antibodies
Immunoenzyme Techniques
Thrombosis
Phospholipids

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Tsutsumi, A., Matsuura, E., Ichikawa, K., Fujisaku, A., Mukai, M., Kobayashi, S., & Koike, T. (1996). Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 39(9), 1466-1474.

Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. / Tsutsumi, Akito; Matsuura, Eiji; Ichikawa, Kenji; Fujisaku, Atsushi; Mukai, Masaya; Kobayashi, Seiichi; Koike, Takao.

In: Arthritis and Rheumatism, Vol. 39, No. 9, 09.1996, p. 1466-1474.

Research output: Contribution to journalArticle

Tsutsumi, A, Matsuura, E, Ichikawa, K, Fujisaku, A, Mukai, M, Kobayashi, S & Koike, T 1996, 'Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus', Arthritis and Rheumatism, vol. 39, no. 9, pp. 1466-1474.
Tsutsumi, Akito ; Matsuura, Eiji ; Ichikawa, Kenji ; Fujisaku, Atsushi ; Mukai, Masaya ; Kobayashi, Seiichi ; Koike, Takao. / Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. In: Arthritis and Rheumatism. 1996 ; Vol. 39, No. 9. pp. 1466-1474.
@article{d5e828733d584366a6d0a745daa2de22,
title = "Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus",
abstract = "Objective. To investigate whether anticardiolipin antibodies (aCL) in patients with systemic lupus erythematosus (SLE) bind to β2-glycoprotein I (β2GPI), and to search for a relationship between the presence of IgG and/or IgM anti-β2GPI antibody and clinical manifestations in SLE patients. Methods. IgG and IgM anti-β2GPI in 308 Japanese SLE patients were measured using phospholipid-independent enzyme immunoassays. Relationships to clinical histories and to various laboratory data were examined. Results. The values of anti-β2GPI and aCL, as measured by conventional enzyme immunoassay, showed a strong correlation, but the anti-β2GPI assay was more useful in distinguishing β2GPI-dependent aCL from β2GPI-independent aCL. The presence of IgG anti-β2GPI was associated with an increased frequency of a history of thrombosis. Comparisons of various laboratory data suggested that the titer of anti-β2GPI may fluctuate with disease activity. Conclusion. The results suggest that pathogenic aCL is directed against structurally altered β2GPI and that enzyme immunoassay for anti-β2GPI may prove useful in evaluating the risk of thrombosis and monitoring the clinical course in patients with SLE.",
author = "Akito Tsutsumi and Eiji Matsuura and Kenji Ichikawa and Atsushi Fujisaku and Masaya Mukai and Seiichi Kobayashi and Takao Koike",
year = "1996",
month = "9",
language = "English",
volume = "39",
pages = "1466--1474",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus

AU - Tsutsumi, Akito

AU - Matsuura, Eiji

AU - Ichikawa, Kenji

AU - Fujisaku, Atsushi

AU - Mukai, Masaya

AU - Kobayashi, Seiichi

AU - Koike, Takao

PY - 1996/9

Y1 - 1996/9

N2 - Objective. To investigate whether anticardiolipin antibodies (aCL) in patients with systemic lupus erythematosus (SLE) bind to β2-glycoprotein I (β2GPI), and to search for a relationship between the presence of IgG and/or IgM anti-β2GPI antibody and clinical manifestations in SLE patients. Methods. IgG and IgM anti-β2GPI in 308 Japanese SLE patients were measured using phospholipid-independent enzyme immunoassays. Relationships to clinical histories and to various laboratory data were examined. Results. The values of anti-β2GPI and aCL, as measured by conventional enzyme immunoassay, showed a strong correlation, but the anti-β2GPI assay was more useful in distinguishing β2GPI-dependent aCL from β2GPI-independent aCL. The presence of IgG anti-β2GPI was associated with an increased frequency of a history of thrombosis. Comparisons of various laboratory data suggested that the titer of anti-β2GPI may fluctuate with disease activity. Conclusion. The results suggest that pathogenic aCL is directed against structurally altered β2GPI and that enzyme immunoassay for anti-β2GPI may prove useful in evaluating the risk of thrombosis and monitoring the clinical course in patients with SLE.

AB - Objective. To investigate whether anticardiolipin antibodies (aCL) in patients with systemic lupus erythematosus (SLE) bind to β2-glycoprotein I (β2GPI), and to search for a relationship between the presence of IgG and/or IgM anti-β2GPI antibody and clinical manifestations in SLE patients. Methods. IgG and IgM anti-β2GPI in 308 Japanese SLE patients were measured using phospholipid-independent enzyme immunoassays. Relationships to clinical histories and to various laboratory data were examined. Results. The values of anti-β2GPI and aCL, as measured by conventional enzyme immunoassay, showed a strong correlation, but the anti-β2GPI assay was more useful in distinguishing β2GPI-dependent aCL from β2GPI-independent aCL. The presence of IgG anti-β2GPI was associated with an increased frequency of a history of thrombosis. Comparisons of various laboratory data suggested that the titer of anti-β2GPI may fluctuate with disease activity. Conclusion. The results suggest that pathogenic aCL is directed against structurally altered β2GPI and that enzyme immunoassay for anti-β2GPI may prove useful in evaluating the risk of thrombosis and monitoring the clinical course in patients with SLE.

UR - http://www.scopus.com/inward/record.url?scp=0029790008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029790008&partnerID=8YFLogxK

M3 - Article

C2 - 8814057

AN - SCOPUS:0029790008

VL - 39

SP - 1466

EP - 1474

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 9

ER -